Kalytera Therapeutics moves into 2nd phase of clinical trials with CBD drug
ENFLEUR is happy to share an update on the progress of clinical-stage pharmaceutical company Kalytera Therapeutics that has moved into the second phase of its CBD-based medication aimed at the prevention of graft versus host disorder (GVHD). GVHD is a potentially life-threatening complication that occurs commonly after bone-marrow transplantation when donor cells attack the patient’s organs. Kalytera Therapeutics has now moved into the second stage of clinical trials, from which they have significant cause for optimism. With 50% of sibling donors and 75% of unrelated donors experiencing some degree of GVHD, there is an urgent, unmet need for GVHD therapies. So far, interim data of the second phase of Kalytera’s efforts have been encouraging, with none of the 12-patient cohort developing the most acute forms of GVHD, grades 3 or 4, while only one of the twelve developed GVHD in its less serious form as a grade 2. In addition to this encouraging finding, Kalytera Therapeutics goes on to notes that CBD also has “a good safety and tolerability profile, with no significant adverse events relating to its use”.
These early results affirm the powerful and essential role that the endocannabinoid system (ECS) plays in regulating homeostasis within the body. For this reason, it is useful to consider whether integrating a high quality CBD supplement makes sense for wellness oriented consumers.
Read more about Kalytera Therapeutics work with CBD and GVHD here.